CEACAM5 and neoplasm: The addition of an anti-HLA-A2 blocking antibody during the killing assay abolished CEA-specific CTL-mediated lysis of LNCaP tumor cells (HLA-A2+) exposed to 10 Gy 223Ra (Figure 2B).